Nearly a quarter-century of clinical trial experience and success
In 2006, New York Oncology Hematology was the proud recipient of two national prestigious awards:
American Society of Clinical Oncology (ASCO) Community Research Award and US Oncology "Outstanding Growth in Accruals"
For more information on clinical trials, please visit:: www.clinicaltrials.gov
For over twenty years, New York Oncology Hematology has participated in clinical trials and has played a pivotal role in the FDA approval process of 24 new anticancer drugs. We work closely with leading pharmaceutical and biotechnology companies in such areas as chemotherapy, radiation therapy and immunotherapy.
We have a unique research infrastructure that includes a dedicated research staff and a standardized Institutional Review Board approval process. This highly efficient organization helps speed drugs from the research lab into patient care, as quickly as possible while providing the highest quality care to our patients.
NYOH participates in Phase I/II and III clinical trials. Trials include all major solid tumor types, hematologic malignancies and supportive care. Our US Oncology affiliation provides us with a robust panel of clinical trial options for our patients.
We also participate in National Cancer Institute (NCI) sponsored research through the Eastern Cooperative Oncology Group (ECOG), the National Surgical Adjuvant Breast and Bowel Project (NSABP), and the Radiation Therapy Oncology Group (RTOG).
The End of Cancer Begins with Research.